(Q37383301)

English

S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

scientific article published on September 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013. (English)

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

27

object named as

N Arnold

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

author name string

U Wagner

1

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

P Harter

2

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

F Hilpert

3

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

S Mahner

4

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

A Reuß

5

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

A du Bois

6

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

E Petru

7

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

W Meier

8

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

P Ortner

9

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

K König

10

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

K Lindel

11

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

D Grab

12

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

P Piso

13

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

O Ortmann

14

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

I Runnebaum

15

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

J Pfisterer

16

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

D Lüftner

17

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

N Frickhofen

18

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

F Grünwald

19

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

B O Maier

20

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

J Diebold

21

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

S Hauptmann

22

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

F Kommoss

23

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

G Emons

24

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

B Radeleff

25

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

M Gebhardt

26

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

G Calaminus

28

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

I Weisse

29

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

J Weis

30

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

J Sehouli

31

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

D Fink

32

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

A Burges

33

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

A Hasenburg

34

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

C Eggert

35

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

publication date

1 September 2013

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Geburtshilfe und Frauenheilkunde: Ergebnisse der Forschung für die Praxis

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

73

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

9

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

874-889

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Screening for gynaecologic cancers in genetically predisposed women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Optimal primary surgical treatment for advanced epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Effect of Screening on Ovarian Cancer Mortality

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Clinical trials in recurrent ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Surgery of ovarian tumors in children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Moving Toward Personalized Medicine: Treatment-Focused Genetic Testing of Women Newly Diagnosed With Ovarian Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Interval debulking surgery for advanced epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

ESUR guidelines: ovarian cancer staging and follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Interventions for the treatment of borderline ovarian tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Maintenance chemotherapy for ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Surgical technique of diaphragm full-thickness resection and trans-diaphragmatic decompression of pneumothorax during cytoreductive surgery for ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Pediatric ovarian malignancies: how efficacious are current staging practices?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Clinical recommendation on fertility preservation in borderline ovarian neoplasm: ovarian stimulation and oocyte retrieval after conservative surgery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Tamoxifen for relapse of ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Predicting the response of advanced cervical and ovarian tumors to therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Immunology of gynecologic neoplasms: analysis of the prognostic significance of the immune status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Gene expression profiling and prediction of clinical outcome in ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Chemosensitivity and chemoresistance testing in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Laparoscopy versus laparotomy for FIGO Stage I ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Surgical outcomes in women with ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Topotecan for ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Germ cell tumors of the ovary

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Management of ovarian stromal cell tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Management of ovarian germ cell tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Fertility preservation options for women with malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Primary surgery for ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Characterization of BRCA1 and BRCA2 mutations in a large United States sample

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Role of conservative surgery in ovarian cancer: the European experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

What is the role of conservative primary surgical management of epithelial ovarian cancer: the United States experience and debate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Conservative management of epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Fertility-sparing options for patients with gynecologic malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Adjuvant chemotherapy improves survival after resection of stage 1 ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Société Francaise d'Oncologie Gynécologique).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Fertility-sparing surgery for malignancies in women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Screening postmenopausal women for ovarian cancer: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Clinical review of 63 cases of sex cord stromal tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Results of conservative management of epithelial malignant and borderline ovarian tumours.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Laparoscopic management of adnexal masses: a gold standard?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Epithelial ovarian cancer: prevention, diagnosis, and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

High-dose chemotherapeutic approaches to ovarian cancer management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Chemotherapy for ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCA mutations. Austrian Hereditary Breast and Ovarian Cancer Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Surgical management of ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: a report of the pediatric oncology group and the children's cancer group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Epithelial ovarian carcinoma in the reproductive age group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Staging Laparotomy in Early Ovarian Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

The CA 125 tumour-associated antigen: a review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Hormone replacement therapy and survival after surgery for ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Treatment of germ cell tumors in children: Results of European trials for testicular and non-testicular primary sites

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

9 September 2017

Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

14 September 2017

Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

14 September 2017

Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

14 September 2017

A randomized study of screening for ovarian cancer: a multicenter study in Japan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

14 September 2017

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

14 September 2017

Clinicopathologic review of 118 granulosa and 82 theca cell tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

14 September 2017

Prognostic factors in adult granulosa cell tumor of the ovary

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

28 September 2017

A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

28 September 2017

Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

28 September 2017

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

26 June 2018

Two for good measure: six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

26 June 2018

Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

26 June 2018

The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

26 June 2018

Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

26 June 2018

Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

26 June 2018

The effect of hysterectomy on survival of patients with borderline ovarian tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Incorporation of bevacizumab in the primary treatment of ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Adult granulosa cell tumors of the ovary: tumor dissemination pattern at primary and recurrent situation, surgical outcome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Prediction of residual disease after primary cytoreductive surgery for advanced-stage ovarian cancer: accuracy of clinical judgment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Evaluation of pelvic posterior exenteration in the management of advanced-stage ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Characteristics and management of diaphragm involvement in patients with primary advanced-stage ovarian, fallopian tube, or peritoneal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gyna

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Should adnexal mass size influence surgical approach? A series of 186 laparoscopically managed large adnexal masses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Simple ultrasound-based rules for the diagnosis of ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Association of lymphadenectomy and survival in stage I ovarian cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Development of an evidence-based algorithm for the management of ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

A qualitative study of the information needs of high-risk women undergoing prophylactic oophorectomy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Surgical staging of carcinoma of the ovaries

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

2 September 2018

Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

3 December 2018

Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

3 December 2018

Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

3 December 2018

Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3859160

3 December 2018

Causes of postoperative mortality after surgery for ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cystectomy for immature teratoma of the ovary

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Surgery of borderline tumors of the ovary: retrospective comparison of short-term outcome after laparoscopy or laparotomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A new prognostic model for FIGO stage 1 epithelial ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of a soluble OX40 isoform: development of a specific and quantitative immunoassay

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatme

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome of patients with early ovarian cancer undergoing three courses of adjuvant chemotherapy following complete surgical staging

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Primary cytoreductive surgery for epithelial ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term follow-up of serous ovarian tumors of low malignant potential

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of surgical staging in patients with macroscopic "stage I" ovarian borderline tumours: analysis of a continuous series of 101 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (A

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intervention debulking surgery in advanced epithelial ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of cytoreductive surgery with pelvic and paraaortic lymphadenectomy and intermittent cisplatin-based combination chemotherapy for improvement of long-term survival in ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of Recurrence of Ovarian Granulosa Cell Tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomised phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer: the Finnish Ovarian Cancer (FINOVA) study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival and prognostic factors in early-stage epithelial ovarian carcinoma treated with taxane-based adjuvant chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Secondary surgical cytoreduction for advanced ovarian carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Laparoscopy compared with laparoscopically guided minilaparotomy for large adnexal masses: a randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systematic Lymphadenectomy for Survival in Epithelial Ovarian Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second-look laparotomy in the management of malignant germ cell tumors of the ovary

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Conservative surgery for stage I ovarian carcinoma in women of childbearing age

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence of subclinical metastasis in stage I and II ovarian carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cisplatin, vinblastine, and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

cis-platinum/vinblastine/bleomycin combination chemotherapy in advanced or recurrent granulosa cell tumors of the ovary

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of secondary cytoreductive surgery in ovarian cancer relapse: Who will benefit? A systematic analysis of 240 consecutive patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients' survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24771937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1055/S-0033-1350713

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37383301&oldid=2103356974"